HomeA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Previous close
R$71.74
Year range
R$36.23 - R$85.44
Market cap
31.48B USD
Avg Volume
38.00
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 593.17M | 34.90% |
Operating expense | 595.51M | 26.63% |
Net income | -83.76M | 39.24% |
Net profit margin | -14.12 | 54.96% |
Earnings per share | 0.06 | 107.79% |
EBITDA | -90.99M | 11.59% |
Effective tax rate | 56.81% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.69B | 10.46% |
Total assets | 4.24B | 10.71% |
Total liabilities | 4.17B | 3.02% |
Total equity | 67.09M | — |
Shares outstanding | 129.46M | — |
Price to book | 137.96 | — |
Return on assets | -6.23% | — |
Return on capital | -9.44% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -83.76M | 39.24% |
Cash from operations | -94.66M | -217.71% |
Cash from investing | -52.91M | 78.01% |
Cash from financing | 31.00M | -20.98% |
Net change in cash | -133.85M | 39.25% |
Free cash flow | -110.30M | -165.23% |
About
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Founded
Jun 14, 2002
Website
Employees
2,230
